• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

LifeScan CEO Valerie Asbury retires from glucose management company

January 30, 2026 By Sean Whooley

LifeScan CEO Valerie Asbury (1)
Retiring LifeScan CEO Valerie Asbury. [Image from LinkedIn]
LifeScan CEO Valerie Asbury said on social media today that she is retiring from the glucose management technology developer.

On LinkedIn, Asbury said she plans to step away after more than 15 years at the company.

“Today marks my last day at LifeScan, and while it is bittersweet, I am deeply grateful for the remarkable journey we have shared together over the past 15+ years,” Asbury wrote. “LifeScan has been much more than a workplace; it has been a vibrant community of colleagues, friends, and partners who have inspired me and helped me grow. The years have brought moments of innovation, learning, and many achievements, all made possible by the people I was fortunate enough to work alongside. Every new challenge was met together, and each success felt sweeter with your support and encouragement.”

The CEO departs just after the Malvern, Pennsylvania-based company emerged from Ch. 11 in December. Through that process, Lifescan said it eliminated more than 75% of its debt. This gives it the financial flexibility to move forward with its glucose management technology.

In connection with the emergence, LifeScan is now owned by a group of its existing lenders. That includes Canyon Parnters and Brigade Capital Management. The company expects to move forward serving more than 20 million people with its OneTouch brand backed by a stronger balance sheet and committed new ownership group.

The company develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management.

“While I look forward to what comes next, leaving LifeScan is not easy,” Asbury concluded. “This company has been a family and a home away from home, and I am proud of what we have accomplished together.”

Filed Under: Business/Financial News, Diabetes, Patient Monitoring, Personnel Tagged With: lifescan, Personnel Moves

IN CASE YOU MISSED IT

  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS